SEEL Stock Soars on 2019 Strategy

Short sellers have been piling on SEEL stock

Deputy Editor
Mar 29, 2019 at 10:06 AM
facebook twitter linkedin


Pharmaceutical concern Seelos Therapeutics Inc (NASDAQ:SEEL) is at the top of the Nasdaq after announcing its 2019 plans. The company anticipates it will dose the first patient with the life-threatening spinal disease Sanfilippo syndrome in a mid-stage trial with the company's experimental Trehalose treatment in the second quarter. The company also announced an early stage study of its ketamine PTSD treatment this summer. As a result, the shares are up 27.3% at $3.64.

SEEL stock has been struggling to rally atop the $4 mark for some time, as level that has acted as a ceiling for the shares. The equity bottomed out at an all-time low of $1.45 on Mar. 4, before nearly doubling later that week. SEEL has since pulled back for these highs, with downward pressure recently emerging at its 40-day moving average. However, today's jump has the penny stock breaking north of its 50-day trendline for the first time since its intraday spike on Mar. 8. 

Short interest has skyrocketed on the stock in 2019, up over 1,400%. Shares sold short now represent a quarter of the stock's available float. Should these bearish bets begin to unwind, some additional tailwinds could help SEEL on its next leg higher. 

 

 

 

Bernie's Best Stock Bets for Summer 2021

1608308875

 




 
Special Offers from Schaeffer's Trading Partners